MVT 1075

Drug Profile

MVT 1075

Alternative Names: 177Lu Human Monoclonal Antibody 5B1; 177Lu- CHX-A″-DTPA-HuMAb-5B1; 177Lu-DTPA-HuMab-5B; 90Y- CHX-A″-DTPA-HuMAb-5B1; HuMab 5B1 radioimmunotherapy agent - MabVax; HuMab-5B1 conjugated Actinium225-radioimmunotherapy agent; MVT 1916; MVT-1075; radiolabeled HuMab 5B1 antibody - MabVax

Latest Information Update: 07 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antibodies; Antineoplastics; Immunoconjugates; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 28 Feb 2018 Interim adverse events data from a phase I trial in Pancreatic cancer released by MabVax Therapeutics
  • 18 Dec 2017 MabVax Therapeutics completes enrolment in its phase I trial for Pancreatic, Colorectal and Lung cancer (NCT03118349)
  • 27 Jun 2017 Phase-I clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top